Lisbon, Nov 9 (Prensa Latina) Patients with two of the three most common types of advanced breast cancer now have a mean survival time of at least five years, double that of a decade ago, it was known today.
–
According to data from a panel of experts at the Sixth International Consensus Conference on Advanced Breast Cancer, one of the most common subtypes of advanced breast cancer is hormone-dependent or estrogen receptor-positive (ER +) because its growth is fueled by the hormone. estrogen
The other is known as HER2 + because cancer cells make too much of a protein known as HER2, which stimulates their growth.
During the last decade, the average survival of these types of advanced breast cancer, which together represent 85 percent of cases, has increased from one or two years to five, said the report of the international conference held virtually in the Portuguese capital.
“This means that half of the patients with these diseases can live more than five years, and some up to 10,” he said.
However, cancer known as triple negative because it does not feed on estrogen and does not produce excess HER2, has fewer treatment options and, consequently, patients have a worse survival.
Despite that evidence, the experts reported, in the past two years, hope has risen for this subtype as well, with two new treatments providing some survival benefit.
In the newly agreed guidelines for advanced breast cancer, experts say that patients with this subtype should have access to new drugs such as govitecan sacituzumab and anti-PD-L1 agents, especially pembrolizumab.
The Advanced Breast Cancer Conference and the Global Alliance for Advanced Breast Cancer agreed on this occasion to double the survival of patients with the disease by 2025.
jha/cdg
–
– .
:quality(75)/cdn.jwplayer.com/v2/media/F3c4mNsD/poster.jpg "Blooper in Liga MX: Roger Martínez touched the ball twice in a penalty and was disallowed | VIDEO | SPORT-TOTAL")